5-[2-((S)-1-cyclopropyl-ethyl)-7-methyl-1-oxo-2,3-dihydro-1H-isoindol-5-yl]-isoxazole-3-carboxylic acid methylamide | 1198309-82-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 5-[2-((S)-1-cyclopropyl-ethyl)-7-methyl-1-oxo-2,3-dihydro-1H-isoindol-5-yl]-isoxazole-3-carboxylic acid methylamide
• 英文别名: 5-[2-[(1S)-1-cyclopropylethyl]-7-methyl-1-oxo-3H-isoindol-5-yl]-N-methyl-1,2-oxazole-3-carboxamide
• CAS: 1198309-82-8
• 化学式: C₁₉H₂₁N₃O₃
• 分子量: 339.394
• InChiKey: WBUANNDCVMQTQT-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  75.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators 286
  申请人：Cacciola Joseph

  公开号：US20090306158A1

  公开（公告）日：2009-12-10

  Compounds in accord with Formula I: wherein R 1 , R 2 , R 3 and R 4 are as defined in the specification, pharmaceutically acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.

  符合公式I的化合物：其中R1、R2、R3和R4如规范中定义的，药学上可接受的盐，制备方法，含有该化合物的药物组合物以及使用该药物组合物的方法。
• Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286
  申请人：Cacciola Joseph

  公开号：US20100022545A1

  公开（公告）日：2010-01-28

  Compounds in accord with Formula I: wherein R 1 , R 2 , R 3 and R 4 are as defined in the specification, pharmaceutically acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.

  符合公式I的化合物：其中R1、R2、R3和R4如规范中所定义，药学上可接受的盐，制备方法，含有该化合物的制药组合物以及使用该组合物的方法。
• METABOTROPIC GLUTAMATE RECEPTOR ISOXAZOLE LIGANDS AND THEIR USE AS POTENTIATORS
  申请人：Cacciola Joseph

  公开号：US20100324044A1

  公开（公告）日：2010-12-23

  Compounds in accord with Formula I: wherein R 1 , R 2 , R 3 and R 4 are as defined in the specification, pharmaceutically acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.

  符合公式I的化合物：其中R1、R2、R3和R4如规范所定义，药学上可接受的盐，制备方法，含有该化合物的制药组合物，以及使用它们的方法。
• Use of an isoxazole derivative for the treatment of withdrawal symptom
  申请人：AstraZeneca AB

  公开号：EP2772492A1

  公开（公告）日：2014-09-03

  Compounds in accord with Formula I: wherein R1, R2, R3 and R4 are as defined in the specification, pharmaceutically acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.

  符合式 I 的化合物： 其中 R1、R2、R3 和 R4 如说明书中定义的化合物、药学上可接受的盐、制造方法、含有这些化合物的药物组合物和使用方法。
• ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS
  申请人：AstraZeneca AB

  公开号：EP2303872B1

  公开（公告）日：2014-04-16